Skip to Content

International Stem Cell Corp ISCO

Morningstar Rating
$0.07 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ISCO is trading at a 846% premium.
Price
$0.07
Fair Value
$1.52
Uncertainty
Extreme
1-Star Price
$1.33
5-Star Price
$5.27
Economic Moat
Nxyc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ISCO is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.07
Day Range
$0.070.07
52-Week Range
$0.050.15
Bid/Ask
$0.05 / $0.11
Market Cap
$577,116.45
Volume/Avg
300 / 1,788

Key Statistics

Price/Earnings (Normalized)
45.32
Price/Sales
0.07
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
29

Valuation

Metric
ISCO
Price/Earnings (Normalized)
45.32
Price/Book Value
Price/Sales
0.07
Price/Cash Flow
0.84
Price/Earnings
ISCO

Financial Strength

Metric
ISCO
Quick Ratio
0.41
Current Ratio
0.72
Interest Coverage
−1.24
Quick Ratio
ISCO

Profitability

Metric
ISCO
Return on Assets (Normalized)
3.31%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
391.46%
Return on Assets
ISCO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
DkrtswjpzzFbgh$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
HmxdlbpcCddmtm$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
NcvcnlwtRjgyrv$117.2 Bil
Moderna Inc
MRNA
LhrlfpyXstk$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
ZtmqybvyRzyqwbg$30.1 Bil
argenx SE ADR
ARGX
JjdmwyjcHywn$28.0 Bil
BioNTech SE ADR
BNTX
RhqmmrycnKtdbl$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
RfgtgvhsbJbczhh$16.0 Bil
United Therapeutics Corp
UTHR
MrfqcpssHhsft$14.6 Bil
Incyte Corp
INCY
RzxdmyxzYvxqps$13.0 Bil

Sponsor Center